<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375465</url>
  </required_header>
  <id_info>
    <org_study_id>Eur-002</org_study_id>
    <nct_id>NCT01375465</nct_id>
  </id_info>
  <brief_title>The 001-DIOR Multicenter Registry</brief_title>
  <official_title>The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurocor GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurocor GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 001 DIOR study is a prospective, multicenter registry of percutaneous coronary
      intervention (PCI) to assess the clinical success, efficacy and safety of the
      Paclitaxel-eluting balloon DIOR (Eurocor GmbH, Germany) for the treatment of de novo ostial
      bifurcated lesions (001 of Medina classification). The DIOR balloon will be used to treat the
      stenotic site branch.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>6 months</time_frame>
    <description>MACE rate defined as the rate of cardiac death and/or myocardial infarction (MI) and/or target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization (TVR) rate, either symptom or ischemia-driven</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment treated thrombosis (STT), according to ARC definitions</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 months</time_frame>
    <description>Late lumen loss determinated by control angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Dior</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DIOR drug-eluting PTCA balloon</intervention_name>
    <description>Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)</description>
    <arm_group_label>Dior</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo bifurcated lesions 001 of Medina classification, with significant stenosis
             only in the ostium of the side branch and a reference vessel diameter is bigger or
             equal 2.0mm; the DIOR balloon will be used to the treat the side branch.

          -  The patient has clinical evidence of myocardial ischemia (stable or unstable angina,
             acute and non acute myocardial infarction, silent ischemia: ECG, exercise test,
             etz...)

          -  As the maximal length of the DIORTM balloon is 30 mm, all eligible lesions should be
             no longer than 25 mm to ensure an adequate drug elution in the treated segment,
             avoiding the phenomenon of &quot;geographical miss&quot; .

          -  Target lesion(s) stenosis is more or equal 50% by visual estimation.

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Any serious disease that might limit patient survival to less than one year

          -  Inability to perform clinical follow-up for a period of 1 year

          -  Left main bifurcation lesions: ostial left circumflex or ostial left anterior
             descending artery stenosis.

          -  Lesion length &gt; 25 mm

          -  Target vessel reference diameter &lt; 2mm

          -  Stenosis &lt; 50% of the reference luminal diameter

          -  Severe angiographic calcification at the level of the target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Serra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Pau, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatriz Vaquerizo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Pau, Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Trías i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

